BRPI0517387A8 - Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas - Google Patents
Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicasInfo
- Publication number
- BRPI0517387A8 BRPI0517387A8 BRPI0517387A BRPI0517387A BRPI0517387A8 BR PI0517387 A8 BRPI0517387 A8 BR PI0517387A8 BR PI0517387 A BRPI0517387 A BR PI0517387A BR PI0517387 A BRPI0517387 A BR PI0517387A BR PI0517387 A8 BRPI0517387 A8 BR PI0517387A8
- Authority
- BR
- Brazil
- Prior art keywords
- allergy
- treatment
- cell proliferation
- neoplastic cell
- sense oligonucleotides
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 3
- 208000026935 allergic disease Diseases 0.000 title abstract 3
- 230000007815 allergy Effects 0.000 title abstract 3
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 210000005170 neoplastic cell Anatomy 0.000 title abstract 2
- 102000004499 CCR3 Receptors Human genes 0.000 abstract 1
- 108010017316 CCR3 Receptors Proteins 0.000 abstract 1
- 206010014950 Eosinophilia Diseases 0.000 abstract 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 abstract 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 abstract 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 abstract 1
- 102000010786 Interleukin-5 Receptors Human genes 0.000 abstract 1
- 108010038484 Interleukin-5 Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/331—Universal or degenerate base
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62320604P | 2004-10-29 | 2004-10-29 | |
| PCT/CA2005/001656 WO2006045202A1 (en) | 2004-10-29 | 2005-10-27 | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0517387A BRPI0517387A (pt) | 2008-10-07 |
| BRPI0517387A8 true BRPI0517387A8 (pt) | 2017-07-11 |
Family
ID=36226992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517387A BRPI0517387A8 (pt) | 2004-10-29 | 2005-10-27 | Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8119790B2 (enExample) |
| EP (1) | EP1812075B1 (enExample) |
| JP (1) | JP5314283B2 (enExample) |
| CN (1) | CN101087623B (enExample) |
| AU (1) | AU2005299218B2 (enExample) |
| BR (1) | BRPI0517387A8 (enExample) |
| CA (1) | CA2584457C (enExample) |
| ES (1) | ES2450929T3 (enExample) |
| MX (1) | MX2007005083A (enExample) |
| NZ (1) | NZ554723A (enExample) |
| RU (1) | RU2416412C2 (enExample) |
| WO (1) | WO2006045202A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2285961A4 (en) | 2008-05-15 | 2012-10-17 | Topigen Pharmaceuticals Inc | OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION |
| MX343559B (es) | 2010-04-29 | 2016-11-10 | Ionis Pharmaceuticals Inc | Modulacion de la expresion de transtiretina. |
| SG192869A1 (en) * | 2011-02-24 | 2013-09-30 | Pharmaxis Ltd | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
| WO2013026059A1 (en) * | 2011-08-18 | 2013-02-21 | New York University | Inhibition of oncogenic kras-induced gm-csf production and function |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| CA3002761A1 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3337530A (en) * | 1965-09-20 | 1967-08-22 | Upjohn Co | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US4921757A (en) * | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) * | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4917951A (en) * | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
| GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US6806061B1 (en) * | 1995-01-19 | 2004-10-19 | Children's Medical Center Corporation | G protein-coupled receptor gene and methods of use therefor |
| US5874211A (en) | 1995-04-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Chemokine expressed in eosinophils |
| FR2734147B1 (fr) | 1995-05-19 | 1997-10-10 | Klein Jean Michel | Dispositif d'osteosynthese implantable |
| US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
| US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
| US6229006B1 (en) | 1995-12-22 | 2001-05-08 | Smithkline Beecham Corporation | Use of antisense oligodeoxynucleotides to produce truncated proteins |
| AUPN780096A0 (en) | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| CA2252432A1 (en) | 1996-04-26 | 1997-11-06 | Incyte Pharmaceuticals, Inc. | Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr] |
| CA2252850A1 (en) | 1996-04-26 | 1997-11-06 | Merck & Co., Inc. | Eosinophil eotaxin receptor |
| US5807708A (en) * | 1996-07-30 | 1998-09-15 | Millennium Pharmaceuticals, Inc. | Conservin nucleic acid molecules and compositions |
| IL135140A0 (en) | 1997-09-17 | 2001-05-20 | Univ East Carolina | Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications |
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| EP1088066B1 (en) | 1998-06-19 | 2006-11-29 | McGILL UNIVERSITY | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues |
| CA2333901A1 (en) | 1998-08-03 | 2000-02-24 | East Carolina University | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
| US6175004B1 (en) | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
| IL140054A0 (en) | 1999-04-06 | 2002-02-10 | Univ East Carolina | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion |
| ATE293688T1 (de) | 2000-09-06 | 2005-05-15 | Univ Mcgill | Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| DK1406667T3 (da) * | 2001-07-06 | 2008-06-16 | Topigen Pharmaceuticals Inc | Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr |
| ATE348104T1 (de) | 2001-10-29 | 2007-01-15 | Univ Mcgill | Azyklische linker enthaltende oligonukleotide und deren verwendungen |
| MXPA04007403A (es) | 2002-02-01 | 2005-07-01 | Univ Mcgill | Oligonucleotidos que comprenden segmentos alternos y usos de los mismos. |
-
2005
- 2005-10-27 WO PCT/CA2005/001656 patent/WO2006045202A1/en not_active Ceased
- 2005-10-27 ES ES05802169.2T patent/ES2450929T3/es not_active Expired - Lifetime
- 2005-10-27 MX MX2007005083A patent/MX2007005083A/es active IP Right Grant
- 2005-10-27 CA CA2584457A patent/CA2584457C/en not_active Expired - Fee Related
- 2005-10-27 US US11/666,647 patent/US8119790B2/en not_active Expired - Fee Related
- 2005-10-27 RU RU2007119777/15A patent/RU2416412C2/ru not_active IP Right Cessation
- 2005-10-27 JP JP2007538227A patent/JP5314283B2/ja not_active Expired - Fee Related
- 2005-10-27 CN CN2005800448619A patent/CN101087623B/zh not_active Expired - Fee Related
- 2005-10-27 BR BRPI0517387A patent/BRPI0517387A8/pt not_active Application Discontinuation
- 2005-10-27 AU AU2005299218A patent/AU2005299218B2/en not_active Ceased
- 2005-10-27 NZ NZ554723A patent/NZ554723A/en not_active IP Right Cessation
- 2005-10-27 EP EP05802169.2A patent/EP1812075B1/en not_active Expired - Lifetime
-
2011
- 2011-11-21 US US13/301,183 patent/US8202851B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007005083A (es) | 2007-10-03 |
| RU2007119777A (ru) | 2008-12-10 |
| EP1812075B1 (en) | 2013-12-11 |
| US20120065249A1 (en) | 2012-03-15 |
| EP1812075A4 (en) | 2010-04-07 |
| CA2584457C (en) | 2012-10-23 |
| AU2005299218A1 (en) | 2006-05-04 |
| US8202851B2 (en) | 2012-06-19 |
| US20090215861A1 (en) | 2009-08-27 |
| CN101087623A (zh) | 2007-12-12 |
| EP1812075A1 (en) | 2007-08-01 |
| JP2008517953A (ja) | 2008-05-29 |
| NZ554723A (en) | 2009-12-24 |
| CA2584457A1 (en) | 2006-05-04 |
| JP5314283B2 (ja) | 2013-10-16 |
| US8119790B2 (en) | 2012-02-21 |
| AU2005299218A2 (en) | 2008-10-30 |
| RU2416412C2 (ru) | 2011-04-20 |
| ES2450929T3 (es) | 2014-03-25 |
| CN101087623B (zh) | 2012-09-26 |
| WO2006045202A1 (en) | 2006-05-04 |
| BRPI0517387A (pt) | 2008-10-07 |
| AU2005299218B2 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2194129A3 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
| EP2666859A3 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
| UA105390C2 (ru) | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК | |
| NO20084712L (no) | Nye farmasoytiske forbindelser | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| BRPI0613859B8 (pt) | inibidores da comt, seus usos, e composição farmacêutica | |
| CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
| EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
| CL2007002617A1 (es) | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. | |
| UY30319A1 (es) | Formulaciones de inhibidores de dpp iv | |
| ECSP088298A (es) | Modulacion de la expresion del receptor glucocorticoide | |
| BRPI0807146B8 (pt) | compostos inibidores da atividade da akt, seu uso no tratamento de câncer e artrite, bem como composição farmacêutica compreendendo os mesmos | |
| DK1649017T4 (da) | Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer | |
| BR122019021238B8 (pt) | uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd) | |
| BRPI0514371A (pt) | 2, 4 di (aminofenil) pirimidina como inibidores de plk | |
| EP2527444A3 (en) | Antisense oligonucleotide modulation of stat3 expression | |
| CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| WO2006047842A3 (en) | Modified nucleosides for rna interference | |
| BR112012016330B8 (pt) | ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos | |
| BR112021024463A2 (pt) | Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas | |
| ECSP077259A (es) | Derivados de pirimidina | |
| ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
| CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
| WO2007022225A3 (en) | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | |
| CL2004001359A1 (es) | Compuestos derivados de piperazina, composicion farmaceutica, utiles como agentes inhibidores de polimerizacion de la tubulina, inhibidores de celulas tumorales y para tratar cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. |
|
| B25A | Requested transfer of rights approved |
Owner name: PHARMAXIS LTD (AU) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |